

# CHB COMMON GROUND GAZETTE

VOL II/III



FROM PAPER  
TO PRACTICE  
CLINICAL  
APPLICATIONS  
OF EASL  
GUIDELINES  
FOR OPTIMAL  
MANAGEMENT

## CME/CE INFORMATION

**Release Date: June 1, 2010**

**Expiration Date: June 1, 2011**

**Estimated time to complete activity: 1.0 hour**

### HOW TO OBTAIN CME CREDIT

In order to receive CME/CE credit for your participation in this activity, please go to [www.cmeuniversity.com](http://www.cmeuniversity.com) and register or login. Click on "Find Post-tests by Course" on the navigation menu, and search by project ID: 7134. Upon successfully completing the post-test (with a passing score of 70% or better) and the online evaluation form, your certificate will be made available immediately.

### FACULTY

#### Paul Martin, MD

Professor of Medicine and Chief, Division of Hepatology  
Center for Liver Disease  
University of Miami School of Medicine  
Miami, FL

#### Mark Sulkowski, MD

Associate Professor of Medicine  
Medical Director, Viral Hepatitis Center  
Johns Hopkins University School of Medicine  
Baltimore, MD

### TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care providers who care for patients with chronic hepatitis B (CHB), including physicians, physician assistants, nurse practitioners, and registered nurses.

### PROGRAM OVERVIEW

CHB Common Ground Gazette is a CME/CE-certified program providing patient case studies and expert commentary that will demonstrate the clinical applications of the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) Guidelines to further advance the management of care for persons with CHB.

### EDUCATIONAL OBJECTIVES

Upon completion of this activity, the participant will be better able to:

- Employ prevention education for patients at high risk for hepatitis B
- Select treatment strategies for CHB (including treatments for patient living with coinfections, comorbidities, and cirrhosis) based on an understanding of guidelines issued by the European Association for the Study of the Liver
- Compare methods for evaluating antiviral treatment response in CHB patients
- Identify strategies to prevent or manage antiviral resistance in the long-term management of patients with CHB

### PHYSICIAN CONTINUING MEDICAL EDUCATION

#### Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and HealthmattersCME. PIM is accredited by the ACCME to provide continuing medical education for physicians.

### CREDIT DESIGNATION

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

*continued*



This activity is jointly sponsored by Postgraduate Institute for Medicine and HealthmattersCME.

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.

**NURSING CONTINUING EDUCATION****Credit Designation**

This educational activity for 1.1 contact hours is provided by Postgraduate Institute for Medicine.

**Accreditation Statements**

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

**California Board of Registered Nursing**

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485, for 1.3 contact hours.

**DISCLOSURE OF CONFLICTS OF INTEREST**

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

**Paul Martin, MD**

*Consultant:* Bristol-Myers Squibb, Gilead Sciences, Inc.

*Grant/Research Support:* Roche Pharmaceuticals

**Mark Sulkowski, MD**

*Consulting Fees:* Abbott, Anadys Pharmaceuticals, Inc, Boehringer Ingelheim, Genentech, Merck, Pfizer, Roche Pharmaceuticals, Tibotec Pharmaceuticals

*Contracted Research:* Abbott, Boehringer Ingelheim, Genentech, Johns Hopkins University, Merck, Tibotec Pharmaceuticals, Vertex

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following HealthmattersCME manager, James Murphy, reported he does not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity. HealthmattersCME ANCC planner, Carla Molliner, PA-C, MHS, has disclosed the following financial relationship: Consulting Fees for Schering-Plough (Hepatitis C Advisory Board).

**METHOD OF PARTICIPATION**

There are no fees for participating and receiving CME credit for this activity. During the period June 1, 2010, through June 1, 2011, participants must (1) read the learning objectives and faculty disclosures; (2) study the educational activity; (3) complete the post-test by going to <http://www.cmeuniversity.com>, enter Course ID 7134, and record the best answer to each question; and (4) complete the evaluation form and credit request. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

**MEDIA:** Newsletter

**DISCLOSURE OF UNLABELED USE**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), HealthmattersCME, and Gilead Sciences, Inc, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, HealthmattersCME, and Gilead Sciences, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**DISCLAIMER**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



**CME/CE PROGRAM EVALUATION**

Project ID: 7134 - This evaluation is not for credit.

Please see Instructions for Credit on page 1 of the CME/CE information

PIM is committed to excellence in continuing education, and your opinions are critical to us in this effort. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form and **fax it to (646) 674-4888**.

**Please rate your level of agreement by circling the appropriate rating:**

5 = Strongly Agree      4 = Agree      3 = Neutral      2 = Disagree      1 = Strongly Disagree

**Learning Objectives**

	Strongly Agree		Neutral		Strongly Disagree
After participating in this activity, I am now better able to:					
Employ prevention education for patients at high risk for hepatitis B.	5	4	3	2	1
Select treatment strategies for CHB (including treatments for patients living with coinfections, comorbidities, and cirrhosis) based on an understanding of the guidelines issued by the European Association for the Study of the Liver	5	4	3	2	1
Compare methods for evaluating antiviral treatment response in CHB patients	5	4	3	2	1
Identify strategies to prevent or manage antiviral resistance in the long-term management of patients with CHB	5	4	3	2	1

Based upon your participation in this activity, choose the statement(s) that apply:

- I gained new strategies/skills/information that I can apply to my area of practice.
- I plan to implement new strategies/skills/information in my practice.

What strategies/changes do you plan to implement in your practice?

---



---



---

What barriers do you see to making a change in your practice?

---



---



---

# CME/CE PROGRAM EVALUATION

Which of the following best describes the impact of this activity on your performance?

- I will implement the information in my area of practice.
- I need more information before I can change my practice behavior.
- This activity will not change my practice as my current practice is consistent with the information presented.
- This activity will not change my practice as I do not agree with the information presented.

**Please rate your level of agreement by circling the appropriate rating:**

5 = Strongly Agree      4 = Agree      3 = Neutral      2 = Disagree      1 = Strongly Disagree

**The content presented:**

	Strongly Agree	Neutral	Strongly Disagree
Enhanced my current knowledge base	5	4	3
Addressed my most pressing questions	5	4	3
Promoted improvements or quality in health care	5	4	3
Was scientifically rigorous and evidence-based	5	4	3
Avoided commercial bias or influence	5	4	3

Would you be willing to participate in a postactivity follow-up survey?     Yes     No

Please list any topics you would like to see addressed in future educational activities:

---



---

Please check the appropriate box if you would like to receive additional educational materials on:

- Hepatitis     HIV     Both HIV and hepatitis

NAME \_\_\_\_\_

DEGREE \_\_\_\_\_

TITLE \_\_\_\_\_

AFFILIATION \_\_\_\_\_

MAILING ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

E-MAIL \_\_\_\_\_

Additional comments:

---



---